🟢 Biovie is trading 6% up in pre-market with topline results expected by September's end

Biovie is trading 6% up at $2.12, based on its pre-market price versus the September 4, 2026 close of $2.00; the gain may reflect anticipation of upcoming clinical data, but that connection is unconfirmed.

• The latest material update was completion of the ADDRESS-LC treatment phase on August 31, with topline results expected before the end of September 2026.
• No new company-specific announcement dated September 8, 2026 was identified; broader U.S. futures are mostly lower, so overall market sentiment cannot confidently explain the move.